Teladoc paid $65M for home-testing firm Catapult as a 'tuck-in'

Teladoc is a publicly traded telemedicine provider; Catapult is a Dallas-based home testing company

At-home wellness exams — vitals, blood samples, virtual nurse consults — can anchor integrated preventive care and steady Teladoc's core

$65M, all cash

Home diagnostics boomed during the pandemic, then consolidated in waves: dozens of deals starting with Ro's 2021 purchase of Kit, Truepill to LetsGetChecked for $525M, Imaware's acquisition and sale, Thirty Madison's Nurx and Pill Club deals, and Everly Health's three-company spree in 2021.

Teladoc — still carrying the weight of its $18.5B Livongo purchase in 2020, a historic $13.7B loss in 2022 mostly from the Livongo write-off, and a market cap below $2B — agreed in February 2025 to buy Catapult Health for $65M in cash. Leerink analysts called it 'a logical tuck-in deal' but cautioned that 'given what has been a choppy M&A history, we think tuck-ins are reasonable, but also note that the biggest driver of improved stock performance remains stabilizing/improving the core.'

Preventive, at-home exams extend Teladoc's virtual care from sick visits into routine detection.

$65M in cash is deliberately small next to the $18.5B Livongo mistake — a tuck-in, not a transformation.

Home testing was consolidating around Teladoc's peers, making standing still the riskier option.

Analysts openly tied the deal's value to fixing the core business, not to Catapult's $30M revenue.

A giant's second act in a category often starts with small cash tuck-ins rather than another moonshot — but the core business still sets the verdict.

The deal was expected to close in Q1 2025. Leerink flagged that the fit still needed proving and that stabilising the core remained the real driver of the stock.